Contact

It's the GeneMedi's summary page for Target/Biomarker Introduction of IL2RA. The page also collects GeneMedi's different modalities and formats products for IL2RA in therapeutics/drug discovery and IVD diagnostics, which is including antibody, ADC, bispecific, antigen, ORF vector, VLP, etc. With GeneMedi's target-insight database-GM ITD database, the IL2RA target is also connected to human indications/diseases/conditions/MOA.

Target sublocation: Transmembrane Protein.

The interleukin 2 (IL2) receptor alpha (IL2RA) and beta (IL2RB) chains, together with the common gamma chain (IL2RG), constitute the high-affinity IL2 receptor. Homodimeric alpha chains (IL2RA) result in low-affinity receptor, while homodimeric beta (IL2RB) chains produce a medium-affinity receptor. Normally an integral-membrane protein, soluble IL2RA has been isolated and determined to result from extracellular proteolyisis. Alternately-spliced IL2RA mRNAs have been isolated, but the significance of each is presently unknown. Mutations in this gene are associated with interleukin 2 receptor alpha deficiency. Patients with severe Coronavirus Disease 2019 (COVID-19), the disease caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), have significantly elevated levels of IL2R in their plasma. Similarly, serum IL-2R levels are found to be elevated in patients with different types of carcinomas. Certain IL2RA and IL2RB gene polymorphisms have been associated with lung cancer risk. [provided by RefSeq, Jul 2020]

Target IDGM-T03313
Target NameIL2RA
Gene ID3559
Gene Official NameIL2RA
Gene AliasCD25, IDDM10, IL2R, IMD41, TCGFR, p55
Protein Sub-locationTransmembrane Protein
CategoryTherapeutics Target, INN Index, Immuno-oncology Target


Pre-made IL2RA-specific INN-index biosimilar (antibody&conjugates)-melredableukin alfa, nemvaleukin alfa, camidanlumab tesirine, daclizumab beta, Daclizumab, Basiliximab, inolimomab, Camidanlumab

Anti-IL2RA therapeutic INN-index antibodies and conjugates are biosimilars expressed by mammalian cell line as a benchmark reference therapeutic antibody for drug discovery, target MOA research, cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Cat No.Products Name (INN Index)INN Name Previous Name Target FormatOrder
GMP-Bios-INN-907Pre-Made Melredableukin Alfa Biosimilar, Fusion Protein targeting IL2RA fused with human IL2 (interleukin 2, IL-2) via a peptidyl linker: Recombinant therapeutic protein targeting CD25/IDDM10/IL2R/IMD41/TCGFR/p55melredableukin alfaIL2RAFusion ProteinINN mab
GMP-Bios-INN-926Pre-Made Nemvaleukin Alfa Biosimilar, Fusion Protein targeting IL2RA fused with human IL2RA (interleukin 2 receptor alpha subunit, IL-2RA, TAC, p55, CD25) 139-303 (1-165): Recombinant therapeutic protein targeting CD25/IDDM10/IL2R/IMD41/TCGFR/p55nemvaleukin alfaIL2RAFusion ProteinINN mab
GMP-Bios-INN-768Pre-Made Camidanlumab Tesirine Biosimilar, Whole Mab Adc, Anti-Il2Ra Antibody: Anti-CD25/IDDM10/IL2R/IMD41/TCGFR/p55 therapeutic antibody Drug Conjugatecamidanlumab tesirineIL2RAWhole mAb ADCINN mab
GMP-Bios-INN-789Pre-Made Daclizumab Beta Biosimilar, Whole Mab, Anti-Il2Ra Antibody: Anti-CD25/IDDM10/IL2R/IMD41/TCGFR/p55 therapeutic antibodydaclizumab betaIL2RAWhole  mAbINN mab
GMP-Bios-ab-129Pre-Made Daclizumab biosimilar, Whole mAb, Anti-IL2RA Antibody: Anti-CD25/IDDM10/IL2R/IMD41/TCGFR/p55 therapeutic antibodyDaclizumabIL2RAWhole mAbINN mab
GMP-Bios-ab-049Pre-Made Basiliximab biosimilar, Whole mAb, Anti-IL2RA Antibody: Anti-CD25/IDDM10/IL2R/IMD41/TCGFR/p55 therapeutic antibodyBasiliximabIL2RAWhole mAbINN mab
GMP-Bios-INN-867Pre-Made Inolimomab Biosimilar, Whole Mab, Anti-Il2Ra Antibody: Anti-CD25/IDDM10/IL2R/IMD41/TCGFR/p55 therapeutic antibodyinolimomabIL2RAWhole  mAbINN mab
GMP-Bios-ab-089Pre-Made Camidanlumab biosimilar, Whole mAb ADC, Anti-IL2RA Antibody: Anti-CD25/IDDM10/IL2R/IMD41/TCGFR/p55 therapeutic antibodyCamidanlumabIL2RAWhole mAb ADCINN mab



Pre-made anti-IL2RA inhibitory monoclonal antibody(mab, blocking antibody inhibitor)-benchmark reference antibody for drug discovery and mechanism of action (MOA) research

Pre-made anti-IL2RA benchmark inhibitory monoclonal antibody(mab, blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). The anti-IL2RA mab is expressed and produced by mammalian cell line as a benchmark reference therapeutic antibody for biological drug discovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Cat No.Antibody NameFormatClassified by tagOrder
GM-Tg-hg-T03313-AbAnti-IL2RA monoclonal antibodymabBiofunctional antibody, Therapeutics Target antibodymonoclonal antibody.




GENEMEDI
6th Floor, Building No.2, Kangxin Road 3377, Shanghai, China
Email: [email protected]   [email protected]
Telephone: +86-21-50478399   Fax: 86-21-50478399
Privacy Policy
Chinese Website

Apply for
Free
Sample

Sample FOC application

×